These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Lin C; Kwong AD; Perni RB Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300 [TBL] [Abstract][Full Text] [Related]
11. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247 [TBL] [Abstract][Full Text] [Related]
12. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations. Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708 [TBL] [Abstract][Full Text] [Related]
13. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Lin K; Perni RB; Kwong AD; Lin C Antimicrob Agents Chemother; 2006 May; 50(5):1813-22. PubMed ID: 16641454 [TBL] [Abstract][Full Text] [Related]
14. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey RG; Venkatraman S; Pan W; Parekh T; Pike RE; Ruan S; Liu R; Baroudy B; Agrawal S; Chase R; Ingravallo P; Pichardo J; Prongay A; Brisson JM; Hsieh TY; Cheng KC; Kemp SJ; Levy OE; Lim-Wilby M; Tamura SY; Saksena AK; Girijavallabhan V; Njoroge FG J Med Chem; 2006 May; 49(9):2750-7. PubMed ID: 16640336 [TBL] [Abstract][Full Text] [Related]
15. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants. Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004 [TBL] [Abstract][Full Text] [Related]
16. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies. Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106 [TBL] [Abstract][Full Text] [Related]
18. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Cubero M; Esteban JI; Otero T; Sauleda S; Bes M; Esteban R; Guardia J; Quer J Virology; 2008 Jan; 370(2):237-45. PubMed ID: 18006035 [TBL] [Abstract][Full Text] [Related]
19. Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. Perni RB; Farmer LJ; Cottrell KM; Court JJ; Courtney LF; Deininger DD; Gates CA; Harbeson SL; Kim JL; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao BG; Schairer WC; Tung RD; Van Drie JH; Wilson K; Thomson JA Bioorg Med Chem Lett; 2004 Apr; 14(8):1939-42. PubMed ID: 15050632 [TBL] [Abstract][Full Text] [Related]